178 results on '"Liang, Chris"'
Search Results
2. Race and Gender Representation in College and Career Readiness Research for Students With Emotional Behavioral Disorders.
Catalog
Books, media, physical & digital resources
3. Vorolanib, a novel tyrosine receptor kinase receptor inhibitor with potent preclinical anti-angiogenic and anti-tumor activity
4. Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
5. Preservers of XR Technologies and Transhumanism as Dynamical, Ludic and Complex System
6. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study
7. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
8. Assessing the vulnerability of Africa's freshwater fishes to climate change: A continent-wide trait-based analysis
9. Efficacy and Safety of TLL-018 in Moderate to Severe Chronic Spontaneous Urticaria Patients with Inadequate Response to H1 Antihistamine: Results from a Phase Ⅰb Study
10. Preservers of XR Technologies and Transhumanism as Dynamical, Ludic and Complex System
11. Attitudes of White Student Services Practitioners toward Asian Americans: Research and Recommendations. Research Report.
12. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel
13. Supplemental Figure 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
14. Supplemental Table 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
15. Supplemental Table 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
16. Supplemental Data 10 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
17. Supplemental Data 5 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
18. Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
19. Supplemental Figure 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
20. Supplemental Figure 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
21. Supplemental Data 9 from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
22. Supplemental Data from Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment
23. Supplementary Table Legends 1-5 from Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
24. Supplementary Tables 1-5 from Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
25. Supplementary Figure Legends 1-5 from Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
26. Data from Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
27. Supplementary Figures 1-5 from Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
28. Prioritizing ecological restoration of converted lands in Canada by spatially integrating organic carbon storage and biodiversity benefits.
29. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR
30. Fifteen Years of the 'Journal of Multicultural Counseling and Development': A Content Analysis.
31. Understory Arthropod Diversity in a Mixed Dryland Ecosystem, Hawai‘i1
32. Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
33. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
34. Phase I/II study of vorolanib plus nivolumab in patients with thoracic malignancies: immunotherapy (IO) correlatives to differentiate responders from nonresponders.
35. Validation of Brief Condom Use Attitudes Scales For Spanish Speaking People-who-use-drugs in El Salvador
36. Abstract CT171: Phase I/II study to evaluate the safety and preliminary activity of nivolumab in combination with vorolanib in patients with refractory thoracic tumors
37. Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
38. Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
39. Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.
40. eXalt3: Phase 3 randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients.
41. Dual PI3 K/mTOR inhibition reduces prostate cancer bone engraftment altering tumor-induced bone remodeling
42. Abstract CT151: CNS activity of ensartinib in ALK-positive non-small cell lung cancer patients
43. Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration
44. eXalt3: A phase III study of ensartinib (X-396) in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
45. Pharmacodynamic phase I study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel.
46. P3.02a-001 Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK+ NSCLC
47. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC
48. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC
49. Abstract CT088: Phase I/II trial of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor, in patients with ALK+ non-small cell lung cancer (NSCLC)
50. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC).
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.